• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biomark Diagnostics Inc (CSE:BUX)

0.3200 -0.0250 (-7.25%)
Streaming Delayed Price Updated: 3:32 PM EST, Nov 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,000
Open 0.3400
Bid (Size) 0.3250 (1,000)
Ask (Size) 0.3400 (1,000)
Prev. Close 0.3450
Today's Range 0.3200 - 0.3400
52wk Range 0.1800 - 0.3750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
Today 8:30 EST
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX)... 
Via Newsfile
Topics Artificial Intelligence
BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
October 07, 2025
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer... 
Via Newsfile

Performance

YTD
+60.0%
+60.0%
1 Month
N/A
N/A
3 Month
-13.5%
-13.5%
6 Month
+14.3%
+14.3%
1 Year
+30.6%
+30.6%

More News

Read More
BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy
September 29, 2025
Via Newsfile
Topics Intellectual Property
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
August 12, 2025
Via Newsfile
BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement
December 29, 2023
Via Newsfile
BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay
December 04, 2023
Via Newsfile
Topics Intellectual Property
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term
November 28, 2023
Via Newsfile
BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives
November 14, 2023
Via Newsfile
Topics Artificial Intelligence
BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test
November 07, 2023
Via Newsfile
BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium
October 24, 2023
Via Newsfile
BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team
August 30, 2023
Via Newsfile
Topics Intellectual Property
Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay
August 08, 2023
Via Newsfile
Topics Intellectual Property
BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting
June 05, 2023
Via Newsfile
BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay
May 31, 2023
Via Newsfile
Topics Death Intellectual Property
BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
May 03, 2023
Via Newsfile
BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors
March 16, 2023
Via Newsfile
Biomark Receives Funding Supporting Research and Development Project for Cancer Treatment Monitoring
February 07, 2023
Via Newsfile
BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch
January 11, 2023
Via Newsfile
Topics Climate Change
BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer
November 30, 2021
Via Newsfile
Topics Artificial Intelligence Death
Liquid Biopsy Company BioMark to Present at the 3rd Annual Congress of the International Society of Liquid Biopsy to Be Held October 22, 2021
October 18, 2021
Via Newsfile
Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patients Receiving Immunotherapy
June 29, 2021
Via Newsfile
BioMark Receives $825K Grant to Develop Its Liquid Biopsy Assay for Lung Cancer Screening
June 01, 2021
Via Newsfile
Topics Artificial Intelligence Economy
BioMark Announces Change of Auditor
May 31, 2021
Via Newsfile
Biomark to Open a Diagnostic Laboratory in Quebec
April 29, 2021
Via Newsfile
BioMark Announces Exercise of Warrants and Gain DTC Eligibility for Its Common Shares
April 21, 2021
Via Newsfile

Frequently Asked Questions

Is Biomark Diagnostics Inc publicly traded?
Yes, Biomark Diagnostics Inc is publicly traded.
What exchange does Biomark Diagnostics Inc trade on?
Biomark Diagnostics Inc trades on the Canadian Securities Exchange
What is the ticker symbol for Biomark Diagnostics Inc?
The ticker symbol for Biomark Diagnostics Inc is BUX on the Canadian Securities Exchange
What is the current price of Biomark Diagnostics Inc?
The current price of Biomark Diagnostics Inc is 0.3200
When was Biomark Diagnostics Inc last traded?
The last trade of Biomark Diagnostics Inc was at 11/12/25 03:32 PM ET
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap